This five-volume series provides clinicians with a detailed, up-to-date, well-referenced overview of the latest developments in this rapidly expanding feld. It serves as an
authoritative guide to the diagnosis and treatment of platelet disorders.The primary audience for the series is clinicians, residents and fellows in internal medicine,
cardiology and haematology, as well as clinicians (e.g. neurologists, nephrologists, rheumatologists) and basic scientists who may be concerned with disorders and
cellular mechanisms involving platelets.
Chapter 106: Aspirin.
Chapter 107: P2Y12 inhibitors.
Chapter 108:
GPIIb/IIIa antagonists.
Chapter 109: PAR antagonists.
Chapter 110:
PDE-adenosine reuptake-inhibitor agents.
Chapter 111: Nitric oxide-releasing
or enhancing agents.
Chapter 112: Platelet puringeric receptors as targets
for novel anti-inflammatory drugs.
Chapter 113: Novel approaches to
antiplatelet therapy.
Chapter 114: Antiplatelet therapy in coronary artery
disease.
Chapter 115: Antiplatelet therapy for TIA/stroke.
Chapter 116:
Antiplatelet therapy for PAD.
Chapter 117: Laboratory monitoring-guided
antiplatelet therapy.
Chapter 118: Antiplatelet therapy for venous
thromboembolism.
Chapter 119: Platelets in regenerative medicine.
Chapter
120: Platelet transfusions.
Chapter 121: TPO agonists and agents under
development to increase platelet count.
Chapter 122: In vitro generated
engineered or enhanced platelets.
Chapter 123: Platelets for gene therapy.-
Chapter 124: Platelets as carriers for antitumor therapy.
Prof. Paolo Gresele, MD, PhD, is Professor of Internal Medicine at the Department of Medicine and Surgery of the University of Perugia, Italy. His research interests are mainly focused on hemostatic and thrombotic disorders, with special attention on the role of platelets in hemorrhagic, cardiovascular and inflammatory diseases. He has been President of Italian Society on Hemostasis and Thrombosis, former chair of the Platelet Physiology Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis (ISTH) he is member of the panel of experts on ClinGen Hemostasis/Thrombosis Clinical Domain Working Group and is the current Chair of the Specialized Working Group (SWG) on Thrombocytopenias and Platelet Function Disorders of the European Hematology Association (EHA-SWG).
Dr. José A. López, MD has held academic positions at the University of California, San Francisco and Gladstone Institute for Cardiovascular Disease, at the Baylor College of Medicine in Houston, Texas, and, most recently, at the University of Washington, where he holds the title of Professor of Medicine (Hematology) and Adjunct Professor of Biochemistry and Mechanical Engineering. Dr. López is also Chief Scientific Officer of Bloodworks Northwest, a large regional blood center, and directs the Bloodworks Research Institute, where he also runs an active laboratory.
Dr. López is currently serving as Co-Director of the Translational Research Training in Hematology Program, an international program to assist in fellow-to-faculty transition cosponsored by the European Hematology Association and the American Society of Hematology.
Prof. Dominick J. Angiolillo, MD, PhD. is a Distinguished Professor of Medicine with Tenure status, Chief of Cardiology and Medical Director of the University of Florida Health Cardiovascular Center. He is also the Medical Director of Cardiovascular Research, Program Director of the ACGME-accredited Interventional Cardiology Fellowship program, and Staff Cardiologist and Interventional Cardiologist at the University of Florida Health System. Much of Prof. Angiolillos professional career has been devoted to interventional cardiology and management of patients with acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis, being a key investigator in the clinical development of numerous novel antithrombotic agents for which he has received numerous national and international academic recognitions.
Professor Clive Page, OBE, BSc, PhD, FRSB, FBPhs (Hon), FFPM (Hon) is an Emeritus Professor of Pharmacology, Kings College London. His main research interests are in the pharmacology of inflammation and respiratory disease. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, a NASDAQ listed Company and was instrumental in the discovery and development of Ensifentrine for the treatment of COPD and other respiratory diseases which was recently approved by the FDA. Clive is a recent past President of the British Pharmacological Society and was awarded the Sandoz Prize from the British Pharmacological Society in 1988, The Tanabe Young Investigators Prize from the American College of Clinical Pharmacology in 1996 and the Royal Society of Biology Presidents Medal in 2012 for Outstanding Contributions to the Life Sciences.
Lisainfo e-raamatute kohta